Related references
Note: Only part of the references are listed.Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML
H. Moses Murdock et al.
BLOOD (2022)
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia
Ing S. Tiong et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
Michael Heuser et al.
BLOOD (2021)
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
Maximilian Stahl et al.
BLOOD ADVANCES (2021)
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
Courtney D. DiNardo et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
David P. Steensma et al.
LEUKEMIA (2021)
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
C. D. DiNardo et al.
BLOOD (2020)
The minimal that kills: Why defining and targeting measurable residual disease is the Sine Qua Non for further progress in management of acute myeloid leukemia
Jan Philipp Bewersdorf et al.
BLOOD REVIEWS (2020)
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results.
David Andrew Sallman et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia A Systematic Review and Meta-analysis
Nicholas J. Short et al.
JAMA ONCOLOGY (2020)
Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML
Nicholas J. Short et al.
BLOOD ADVANCES (2020)
Single-cell mutation analysis of clonal evolution in myeloid malignancies
Linde A. Miles et al.
NATURE (2020)
MSK-IMPACT Heme: Validation and clinical experience of a comprehensive molecular profiling platform for hematologic malignancies
Ryan N. Ptashkin et al.
CANCER RESEARCH (2019)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
M. Jongen-Lavrencic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
Felicitas Thol et al.
BLOOD (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group
Marie Balsat et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Measurable residual disease testing in acute myeloid leukaemia
C. S. Hourigan et al.
LEUKEMIA (2017)
Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation
Bartlomiej M. Getta et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
Daisuke Araki et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Assessment of Minimal Residual Disease in Standard-Risk AML
A. Ivey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology
Donavan T. Cheng et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia
Sylvie D. Freeman et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
Monique Terwijn et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
Frank G. Rueckner et al.
BLOOD (2012)
Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Roland B. Walter et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Share Paper
